Redcliffe Labs to invest around Rs 81 crore to expand genetic, specialised testing portfolio

The company, which has a focus on next-generation technologies in the diagnostics space after building an AI (artificial intelligence) platform, has already invested USD 6 million earlier into genetics and specialised testing coverage from prenatal to oncology, neurology, and nephrology, among other segments.

"We plan to add advanced high throughput NGS (next-generation sequencing) facilities at our expanded NRL (national reference lab) site and de-centralised low throughput sequencers across all regional reference labs," Redcliffe Labs Founder & MD Dheeraj Jain said in a statement.

According to a study report by Market Research Future (MRFR), the global market for genetic testing is anticipated to develop at a compound annual growth rate of 11.5 percent and reach a value of over USD 22,800 million between 2019 and 2024.

By the end of 2024, the prescribed genetic testing segment is anticipated to account for more than USD 21,600 million, it claimed.

Read also: Redcliffe Lifetech unit introduces Novaseq 6000 sequencing system to diagnostic technology portfolio

The market for genetic testing in India has grown by over 15 percent to reach Rs 400-500 million.

Redcliffe Labs currently has over 43 laboratories and 1,100-plus authorised collection centres.

The company said it is working towards having an additional 57 laboratories in the next six months. It also plans to have 1,200 collection centres and become accessible in more than 200 cities and 3,500 pin codes by June next year.